Abedi-Valugerdi M - Search Results

1

Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway.

El-Serafi I, Terelius Y, Abedi-Valugerdi M, Naughton S, Saghafian M, Moshfegh A, Mattsson J, Potácová Z, Hassan M. El-Serafi I, et al. Among authors: abedi valugerdi m. PLoS One. 2017 Nov 9;12(11):e0187294. doi: 10.1371/journal.pone.0187294. eCollection 2017. PLoS One. 2017. PMID: 29121650 Free PMC article.

2

Biological half-life of normal and truncated human IgG3 in scid mice.

Hassan MS, Abedi-Valugerdi M, Lefranc G, Hammarström L, Smith CI. Hassan MS, et al. Eur J Immunol. 1991 May;21(5):1319-22. doi: 10.1002/eji.1830210534. Eur J Immunol. 1991. PMID: 2037016

3

Exposure to mercuric chloride during the induction phase and after the onset of collagen-induced arthritis enhances immune/autoimmune responses and exacerbates the disease in DBA/1 mice.

Hansson M, Djerbi M, Rabbani H, Mellstedt H, Gharibdoost F, Hassan M, Depierre JW, Abedi-Valugerdi M. Hansson M, et al. Immunology. 2005 Mar;114(3):428-37. doi: 10.1111/j.1365-2567.2005.02105.x. Immunology. 2005. PMID: 15720444 Free PMC article.

4

Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.

Nilsson C, Forsman J, Hassan Z, Abedi-Valugerdi M, O'Connor C, Concha H, Jansson M, Hassan M. Nilsson C, et al. Exp Hematol. 2005 Mar;33(3):380-7. doi: 10.1016/j.exphem.2004.12.003. Exp Hematol. 2005. PMID: 15730862 Free article.

5

Myeloablative and immunosuppressive properties of treosulfan in mice.

Sjöö F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M, Aschan J, Concha H, Gaughan U, Hassan M. Sjöö F, et al. Exp Hematol. 2006 Jan;34(1):115-21. doi: 10.1016/j.exphem.2005.09.015. Exp Hematol. 2006. PMID: 16413398 Free article.

6

The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.

Sadeghi B, Jansson M, Hassan Z, Mints M, Hägglund H, Abedi-Valugerdi M, Hassan M. Sadeghi B, et al. Bone Marrow Transplant. 2008 May;41(10):895-904. doi: 10.1038/sj.bmt.1705996. Epub 2008 Jan 28. Bone Marrow Transplant. 2008. PMID: 18223695

7

GVHD after chemotherapy conditioning in allogeneic transplanted mice.

Sadeghi B, Aghdami N, Hassan Z, Forouzanfar M, Rozell B, Abedi-Valugerdi M, Hassan M. Sadeghi B, et al. Bone Marrow Transplant. 2008 Dec;42(12):807-18. doi: 10.1038/bmt.2008.261. Epub 2008 Sep 29. Bone Marrow Transplant. 2008. PMID: 18820712

8

Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.

Sadeghi B, Al-Hashmi S, Hassan Z, Rozell B, Concha H, Lundmark C, Grönvik KO, Abedi-Valugerdi M, Hassan M. Sadeghi B, et al. Clin Dev Immunol. 2010;2010:142943. doi: 10.1155/2010/142943. Epub 2010 Dec 21. Clin Dev Immunol. 2010. PMID: 21197273 Free PMC article.

9

Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?

Sadeghi B, Al-Chaqmaqchi H, Al-Hashmi S, Brodin D, Hassan Z, Abedi-Valugerdi M, Moshfegh A, Hassan M. Sadeghi B, et al. Bone Marrow Transplant. 2013 Feb;48(2):284-93. doi: 10.1038/bmt.2012.120. Epub 2012 Jul 23. Bone Marrow Transplant. 2013. PMID: 22825425

10

Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion.

Al Hashmi S, Sadeghi B, Hassan Z, Abedi-Valugerdi M, Lindskog M, Hassan M. Al Hashmi S, et al. Bone Marrow Transplant. 2013 Jun;48(6):843-8. doi: 10.1038/bmt.2012.227. Epub 2012 Nov 26. Bone Marrow Transplant. 2013. PMID: 23178546

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

80 results

Search Page